Postdoctoral Research Associate - Gene Regulation, Single-Cell Multi-omics, and Functional Genomics
St. Jude Children's Research Hospital
Summary
The Cheng Lab at St. Jude Children's Research Hospital is seeking a highly motivated Postdoctoral Research Associate to investigate fundamental mechanisms of gene regulation and genetic variation in human hematopoiesis and blood disorders.
Job description
Our laboratory integrates single-cell multi-omics, functional genomics, human genetics, computational biology, and genetic/epigenetic perturbation to understand how cis-regulatory elements (CREs) control gene expression and how genetic variation in these elements contributes to human phenotypes and disease.
Research Program
Using hematopoiesis as a model system, we study the dynamic organization and function of enhancers, silencers, insulators, and other CREs. Our research addresses three central questions:
- How are CREs spatially and temporally organized across cell types and developmental stages?
- How do common and rare genetic variants in CREs affect hematopoiesis and blood disorders?
- How can CREs be manipulated to improve genetic therapies?
Our previous work has developed high-throughput approaches to map functional CREs regulating red blood cell traits and identified potential targets for therapeutic genome editing in sickle cell disease (SCD) and β-thalassemia. We also develop computational approaches to improve the efficacy and safety of genetic therapies.
Postdoctoral Research
The successful candidate will have flexibility to develop projects within the laboratory's broader research program. Potential directions include:
- Integrating single-cell transcriptomic, epigenomic, and multi-omic data to understand gene regulation and cellular heterogeneity.
- Determining how genetic and structural variation alters cis-regulatory architecture and gene expression.
- Defining regulatory networks and genotype-to-phenotype relationships through computational genomics.
- Functionally testing regulatory elements and genetic variants using CRISPR-based genetic and epigenetic perturbation.
- Translating discoveries in gene regulation into new strategies for genome editing and genetic therapies.
One major NIH-funded project investigates fetal hemoglobin (HbF) regulation in SCD as a model for understanding regulatory heterogeneity. We are integrating single-cell multi-omics, human genetics, chromatin profiling, whole-genome sequencing, and genome editing to determine how genetic and epigenetic variation shapes HbF expression at single-cell resolution and influences therapeutic response and disease severity.
Candidate Qualifications
We welcome candidates with a PhD, MD/PhD, or equivalent degree in genetics, genomics, computational biology, bioinformatics, molecular biology, systems biology, hematology, computer science, or related fields.
Candidates with computational, experimental, or hybrid backgrounds are encouraged to apply. Experience in single-cell genomics, gene regulation/chromatin biology, computational genomics, human genetics, functional genomics, genome editing, or machine learning for genomic data is particularly relevant.
Prior experience in sickle cell disease or erythroid biology is not required.
The Cheng Lab provides an interdisciplinary environment at the interface of gene regulation, functional genomics, human genetics, computational biology, and genome engineering, with access to the extensive scientific and technological resources at St. Jude.
Requirements
- PhD, MD/PhD, or equivalent degree in genetics, genomics, computational biology, bioinformatics, molecular biology, systems biology, hematology, computer science, or related fields
- Experience in single-cell genomics, gene regulation/chromatin biology, computational genomics, human genetics, functional genomics, genome editing, or machine learning for genomic data is particularly relevant
Company overview
St. Jude Children's Research Hospital is a world-renowned pediatric research and treatment institution headquartered in Memphis, Tennessee, dedicated to advancing cures for childhood cancer and other catastrophic diseases. Founded in 1962 by entertainer Danny Thomas, it stands as the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted exclusively to children. The hospital operates on a unique funding model where families never receive bills for treatment, travel, housing, or food, with costs exceeding $2 billion annually primarily supported by donations through its fundraising organization ALSAC. St. Jude treats approximately 8,600 patients each year from all 50 states and around the world, with a focus on acute lymphoblastic leukemia, brain tumors, sickle cell disease, and infectious diseases. The institution employs over 7,000 staff members and maintains eight affiliate clinics across the United States. Through its St. Jude Global initiative, the hospital shares research and treatment protocols internationally, partnering with more than 350 institutions in over 90 countries. St. Jude has been instrumental in increasing childhood cancer survival rates from 20% in 1962 to over 80% today, while maintaining a robust research program that includes gene therapy, bone marrow transplantation, and precision medicine approaches.